BTSG vs NAGE: fair value comparison
BrightSpring Health Services, Inc. and Niagen Bioscience, Inc. · Updated 2026-09-12
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, BTSG currently sits closer to the top of our discount ranking. NAGE carries the stronger quality grade.
| BTSG | NAGE | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $59.16 | $3.13 |
| 12-month range | $29.84–$69.85 | $3.13–$7.89 |
| Sector rank | #46 of 113 Healthcare | #47 of 113 Healthcare |
| Quality grade | D | A |
| Leverage | Moderate | Low |
| Margin trend | Stable | Stable |
| Revenue growth | Strong | Strong |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Mixed | Downtrend |
| DCF cross-check | Overvalued | — |
| 52-week position | The upper-middle quarter | The bottom quarter |
Full single-stock breakdowns: BTSG fair value analysis · NAGE fair value analysis